Dashboard
1
Poor Management Efficiency with a low ROCE of 6.40%
- The company has been able to generate a Return on Capital Employed (avg) of 6.40% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Negative results in Mar 26
4
With ROE of 15.97%, it has a very attractive valuation with a 1.59 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SAR 2,982 Million (Small Cap)
10.00
NA
1.54%
1.27
8.53%
1.57
Revenue and Profits:
Net Sales:
765 Million
(Quarterly Results - Mar 2026)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-52.3%
0%
-52.3%
6 Months
-53.77%
0%
-53.77%
1 Year
-59.41%
0%
-59.41%
2 Years
-43.46%
0%
-43.46%
3 Years
-13.03%
0%
-13.03%
4 Years
-12.11%
0%
-12.11%
5 Years
14.64%
0%
14.64%
Middle East Healthcare Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.85%
EBIT Growth (5y)
25.10%
EBIT to Interest (avg)
2.16
Debt to EBITDA (avg)
5.81
Net Debt to Equity (avg)
1.14
Sales to Capital Employed (avg)
0.71
Tax Ratio
5.79%
Dividend Payout Ratio
15.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.40%
ROE (avg)
9.64%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.59
EV to EBIT
14.14
EV to EBITDA
8.65
EV to Capital Employed
1.25
EV to Sales
1.76
PEG Ratio
1.92
Dividend Yield
1.55%
ROCE (Latest)
8.85%
ROE (Latest)
15.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
765.20
733.60
4.31%
Operating Profit (PBDIT) excl Other Income
138.50
160.10
-13.49%
Interest
43.10
53.50
-19.44%
Exceptional Items
0.00
0.00
Consolidate Net Profit
25.10
162.70
-84.57%
Operating Profit Margin (Excl OI)
97.40%
139.30%
-4.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 4.31% vs 6.44% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -84.57% vs 212.88% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,102.60
2,882.80
7.62%
Operating Profit (PBDIT) excl Other Income
636.50
662.00
-3.85%
Interest
195.30
224.80
-13.12%
Exceptional Items
4.90
47.70
-89.73%
Consolidate Net Profit
309.50
283.90
9.02%
Operating Profit Margin (Excl OI)
125.90%
154.50%
-2.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.62% vs 8.65% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 9.02% vs 1,284.88% in Dec 2024
About Middle East Healthcare Co. 
Middle East Healthcare Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






